Program

DAY 1: Thursday, March 26, 2026
TimeTopicSpeaker
 Introduction 
8:00 AMWelcoming remarks
  • Jeremie Calais, MD, PhD
    UCLA
  • Thomas Hope, MD
    UCSF
  • Phillip J. Koo, MD
    Prostate Cancer Foundation
8:10 AMNuclear medicine in prostate cancer careJohannes Czernin, MD
UCLA
 PSMA PET 
8:20 AMThe problem with our reportsRobert Reiter, MD
UCLA
8:30 AMSPECT versus PET: Optimizing response biomarkersLisa Bodei, MD, PhD
Memorial Sloan Kettering, New York, NY
8:40 AMDoes what we see on PSMA PET matter?Peter Choyke, MD
National Cancer Institute, Bethesda, MD
8:50 AMDiscussion 
 Clinical Trial Updates 
9:10 AMPSMAadditionOliver Sartor, MD
East Jefferson General Hospital (EJGH) Cancer Center, New Orleans, LA
9:20 AMDORA and PEACE-3: Evolving role of Ra-223Michael Morris, MD
Memorial Sloan Kettering, New York, NY
9:30 AMPEACE-6Désirée Deandreis, MD
Gustave Roussy, Villejuif, France
9:40 AMChemo versus PSMA RLTFrançois Bénard, MD
BC Cancer Research Institute, Vancouver, BC
9:50 AMSTAMPEDENick James, MBBS, PhD
Institute of Cancer Research, London, UK
10:00 AMDiscussion 
10:20 AMBREAK 
 New Radioligands and Radionuclides 
10:50 AMIs Astatine the way to go?Tadashi Watabe, MD, PhD
Osaka University, Japan
11:00 AMAc-PSMA: The truth should be told!Matthias Eiber, MD, PhD
Technische Universität München, Germany
11:10 AMDoes dose rate matter? Amanda Walker
AstraZeneca
11:20 AMDiscussion 
 Market and Raw Materials 
11:40 AMThe theranostic revolution: Innovation, investment, and implications Germo Gericke, MD
Ariceum Therapeutics, Berlin, Germany
11:50 AMRaw material supply Nicolas Mario
NucAdvisor, Paris, France
12:00 PMHow we get to the radionuclideJon Engle, PhD
University of Wisconsin,Madison
12:10 PMDiscussion 
12:30 PMLUNCH 
 Approaches to Combination Therapies 
1:30 PMPSMA upfront versus RLT at the endPending
1:40 PMAre alpha or beta particles better for immunogenic priming?Zachary Morris, MD, PhD
University of Wisconsin, Madison
1:50 PMHow important is the bystander effect in RLT?Jean Pierre Pouget, PhD
French National Institute for Health and Medical Research
2:00 PMImmunotherapy beyond checkpoint inhibitorsLawrence Fong, MD
Fred Hutchinson Cancer Center, Seattle, WA 
2:10 PMDiscussion 
 Radiation Sensitivity 
2:30 PMNon-PARP DNA repair enzymes: What are the optimal combinations?Jonathan Chou, MD, PhD
UCSF
2:40 PMDoes dosimetry matter?Pending
2:50 PMTests that predict radiation sensitivity: Experience from space travelKevin Tabury, PhD
Belgian Nuclear Research Center (SCK CEN)
3:00 PMMechanisms of resistance to radioligand therapyChristine Mona, PhD
UCLA
3:10 PMPredicting radiation resistence with ctDNAPending
3:20 PMDiscussion 
 Keynote 
3:40 PMFundamental questions, transformative answers: Driving prostate cancer therapies through basic science Owen Witte, MD
UCLA
4:00 PMCocktail hour 
DAY 2: Friday, March 27, 2026
TimeTopicSpeaker
 Targeting the Cell Surface  
8:00 AMModalities for targeting the cell surfaceAditya Bardia, MD, MPH
UCLA
8:10 AMADCs and BiTEs and their role in prostate cancerTanya B. Dorff, MD
City of Hope, Los Angeles, CA
8:20 AMDLL3: Does target expression determine the method of targeting?Rahul Aggarwal, MD
UCSF
8:30 AMDiscussion 
8:50 AMBREAK 
 Challenges of Radioligand Therapy 
9:20 AMThe expanding theranostic dream: From hype to hard truthsMichael Hofman, MBBS
Peter MacCallum Cancer Centre, Melbourne, Australia
9:35 AMRenal toxicity associated with PSMA targeted therapyInès Camille Azrour, PharmD
UCLA
9:45 AMLong term marrow toxicity: Rates and risk factorsDaniel (Dan) Childs, MD
Mayo Clinic, Rochester, MN
 Radioligand Therapy Tumor Board 
9:55 AMTumor board 
10:55 AMLUNCH 
 Clinical Development 
11:55 AMRegulatory considerations related to PSMA PET imaging in clinical trialsWilliam Maguire, MD
U.S. Food and Drug Administration
12:10 PMIncorporating PSMA PETs in registrational trialsAlicia Morgans, MD, MPH
Dana-Farber Cancer Institute, Boston, MA
12:20 PMHow PCWG4 impacts future trialsMichael Morris, MD
Memorial Sloan Kettering, New York, NY
12:30 PMApproaches to Phase 0/1 DevelopmentAnna Karman, MD, PhD
AdvanCell
12:40 PMDiscussion 
 Developing Novel Radioligands 1 
1:10 PMReview of Phase 1/2 compounds recently publishedJeremie Calais, MD, PhD
UCLA
1:20 PMStruggles with managing radioligand therapy trialsTheranostics Clinical Research Program
1:30 PMDiscussion 
 Developing Novel Radioligands 2 
1:50 PMOptimization of radioligand chemistryJohn Babich, PhD
Ratio Therapeutics
2:00 PMInitial experience with APC3Philipp Backhaus, MD
University of Münster, Germany
2:10 PMDoes FAP have a future: pro / con
  • Matthias Eiber, MD, PhD
    Technische Universität München, Germany
  • Wolfgang Fendler, MD
    University Hospital Essen, Germany
2:20 PMInteractive target session 
2:30 PMDiscussion
  • Thomas Hope, MD
    UCSF
  • Oliver Sartor, MD
    East Jefferson General Hospital (EJGH) Cancer Center, New Orleans, LA
2:50 PMBREAK 
 Wrap-up and Poster Presentations 
3:20 PMWrap-up
  • Thomas Hope, MD
    UCSF
  • Jeremie Calais, MD, PhD
    UCLA
3:30 PMPoster SlamPresenters
4:00 PMCocktail hour